Facing the challenge of multidrug-resistant gram-negative bacilli in Australia

Medical Journal of Australia

Volumn 202, Issue 5, 2015, Pages 243-246

  Harris, Patrick ^a   Paterson, David ^a   Rogers, Benjamin ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SOUTHERN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; COLISTIN; FOSFOMYCIN; MONOBACTAM DERIVATIVE; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; AUSTRALIA; BACTERIAL INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CEPHALOSPORIN RESISTANT ENTEROBACTERIACEAE; CLINICAL DECISION MAKING; COMMUNITY ACQUIRED INFECTION; DISEASE TRANSMISSION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NOTE; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; ENTEROBACTERIACEAE INFECTIONS; MICROBIOLOGY;

AUSTRALIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 84924984412     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.01257     Document Type: Note

References (30)

1. Looke DF, Gottlieb T, Jones CA, et al. Gram-negative resistance: can we combat the coming of a new “Red Plague” [editorial]? Med J Aust 2013; 198: 243-244.
2. World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO, 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf (accessed Jan 2015).
3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta: CDC, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf (accessed Jan 2015).
4. Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum -lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56: 641-648.
5. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
6. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352: 380-391.
7. Bhullar K, Waglechner N, Pawlowski A, et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLOS One 2012; 7: e34953.
8. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
9. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
10. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing gram-negative bacteria. Clin Microbiol Infect 2012; 18: 439-448.
11. Lim CJ, Cheng AC, Kong DC, Peleg AY. Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study. BMC Infect Dis 2014; 14: 126.
12. Australian Group on Antimicrobial Resistance. Gram-negative survey: 2012 antimicrobial susceptibility report. Canberra: AGAR, 2013. http://www.agargroup.org/files/AGAR%20GNB12%20Report%20FINAL.pdf (accessed Jan 2015).
13. Pearson J, Turnidge J, Franklin C, et al. Prevalence of antimicrobial resistances in common pathogenic Enterobacteriaceae in Australia, 2004: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep 2007; 31: 106-112.
14. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2014. http://www.ecdc.europa.eu/en/publications/Publications/antimicrobialresistance-surveillance-europe-2013.pdf (accessed Jan 2015).
15. Rogers BA, Ingram PR, Runnegar N, et al. Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother 2014; 58: 2126-2134.
16. Stuart RL, Kotsanas D, Webb B, et al. Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust 2011; 195: 530-533.
17. Lu PL, Liu YC, Toh HS, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009- 2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents 2012;40 Suppl: S37-S43.
18. Kumar Y, Sood S, Sharma A, Mani KR. Antibiogram and characterization of resistance markers among Escherichia coli isolates from urinary tract infections. J Infect Dev Ctries 2013; 7: 513-519.
19. Chua KY, Grayson ML, Burgess AN, et al. The growing burden of multidrug-resistant infections among returned Australian travellers. Med J Aust 2014; 200: 116-118.
20. Espedido BA, Steen JA, Ziochos H, et al. Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution. PLOS One 2013; 8: e59920.
21. Blyth CC, Pereira L, Goire N. New Delhi metallo-betalactamase- producing enterobacteriaceae in an Australian child who had not travelled overseas. Med J Aust 2014; 200: 386.
22. Australian Commission on Safety and Quality in Health Care. Recommendations for the control of multi-drug resistant gram-negatives: carbapenem resistant enterobacteriaceae. Sydney: ACSQHC, 2013. http://www.safetyandquality.gov.au/wp-content/uploads/2013/12/MRGN-Guide- Enterobacteriaceae-PDF-1.89MB.pdf (accessed Jan 2015).
23. Australian Commission on Safety and Quality in Health Care. Australian guidelines for the prevention and control of infection in healthcare. Canberra: Australian Government, 2010. http://www.nhmrc.gov.au/_files_nhmrc/publications/ attachments/cd33_exec_summary.pdf (accessed Jan 2015).
24. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013; (4): CD003543.
25. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013; 56: 1445-1450.
26. Rodríguez-Baño J, Navarro MD, Retamar P, et al. Lactam/lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum _-lactamaseproducing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54: 167-174.
27. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-1106.
28. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
29. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013; 57: 4605-4607.
30. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 2013; 66: 571-591.